FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029205267> ?p ?o ?g. }

• W2029205267 endingPage "520" @default.
• W2029205267 startingPage "515" @default.
• W2029205267 abstract "<i>Background</i>: Isotretinoin has been used in the past as a differentiation-inducing agent in myelodysplastic syndrome (MDS). ATRA is another retinoic acid derivative and a main therapeutic option in the treatment of acute promyelocytic leukemia (APL). We report the results with ATRA on 5 patients with MDS. <i>Patients and Results</i>: Five patients, 54 to 82 years of age, have been treated with ATRA at a dose level of 45 mg/m² for a period of 3 up to 9 weeks. Diagnosis according to the FAB classification was refractory anemia (RA; 1 case), refractory anemia with excess of blasts (RAEB; 3 cases), and refractory anemia with excess of blasts in transformation (RAEB-t; 1 case). In the preleukemic cases with blast excess, cyto-toxic chemotherapy had been withheld according to age and/or comorbidity. Three patients were treated in a phase II multicenter trial with recombinant human erythropoietin (rh-EPO), 2 of these prior to ATRA therapy, another patient after failure of ATRA therapy. Alltogether these 3 patients failed to respond to rh-EPO. Because of severe granulocytopenia and intermittent infectious complications a simultaneous administration of granulocyte colony-stimulating factor (G-CSF) was necessary in 3 patients. However, ATRA treatment did not show any benefit in case of RAEB, RAEB-t such as prolongation of the transfusion interval for red blood cells or increase of peripheral cell count of any lineage. In one patient with RA we observed a marginal therapeutic activity of ATRA. A prolongation of the transfusion interval with red blood cells (RBC) from 7.1 to 17.2 days has been documented, and an increase in platelet count from 59/nl to a maximum of 158/nl as well. The major side effects in all patients we observed were moderate hypertriglyceridemia, muco-cutaneous dryness, and pruritus. In the partial responding female patient, ATRA treatment had to be cessated because of severe arthralgias and ophthalmic keratitis. <i>Conclusion</i>: In contrast to the remarkable activity in the treatment of APL, in our 5 MDS cases ATRA exhibited no major therapeutic activity, particularly in the 4 preleukemic RAEB cases." @default.
• W2029205267 created "2016-06-24" @default.
• W2029205267 creator A5026821034 @default.
• W2029205267 creator A5047340371 @default.
• W2029205267 creator A5064007709 @default.
• W2029205267 creator A5071077547 @default.
• W2029205267 creator A5077223497 @default.
• W2029205267 date "1994-01-01" @default.
• W2029205267 modified "2023-09-26" @default.
• W2029205267 title "ALL-Trans Retinoic Acid (ATRA) in the Treatment of Myelodysplastic Syndromes: Results in 5 Cases" @default.
• W2029205267 doi "https://doi.org/10.1159/000218467" @default.
• W2029205267 hasPublicationYear "1994" @default.
• W2029205267 type Work @default.
• W2029205267 sameAs 2029205267 @default.
• W2029205267 citedByCount "5" @default.
• W2029205267 countsByYear W20292052672017 @default.
• W2029205267 crossrefType "journal-article" @default.
• W2029205267 hasAuthorship W2029205267A5026821034 @default.
• W2029205267 hasAuthorship W2029205267A5047340371 @default.
• W2029205267 hasAuthorship W2029205267A5064007709 @default.
• W2029205267 hasAuthorship W2029205267A5071077547 @default.
• W2029205267 hasAuthorship W2029205267A5077223497 @default.
• W2029205267 hasConcept C104317684 @default.
• W2029205267 hasConcept C126322002 @default.
• W2029205267 hasConcept C143998085 @default.
• W2029205267 hasConcept C185592680 @default.
• W2029205267 hasConcept C2779963572 @default.
• W2029205267 hasConcept C2780007613 @default.
• W2029205267 hasConcept C2780817109 @default.
• W2029205267 hasConcept C2781121885 @default.
• W2029205267 hasConcept C502942594 @default.
• W2029205267 hasConcept C55493867 @default.
• W2029205267 hasConcept C71924100 @default.
• W2029205267 hasConceptScore W2029205267C104317684 @default.
• W2029205267 hasConceptScore W2029205267C126322002 @default.
• W2029205267 hasConceptScore W2029205267C143998085 @default.
• W2029205267 hasConceptScore W2029205267C185592680 @default.
• W2029205267 hasConceptScore W2029205267C2779963572 @default.
• W2029205267 hasConceptScore W2029205267C2780007613 @default.
• W2029205267 hasConceptScore W2029205267C2780817109 @default.
• W2029205267 hasConceptScore W2029205267C2781121885 @default.
• W2029205267 hasConceptScore W2029205267C502942594 @default.
• W2029205267 hasConceptScore W2029205267C55493867 @default.
• W2029205267 hasConceptScore W2029205267C71924100 @default.
• W2029205267 hasIssue "5" @default.
• W2029205267 hasLocation W20292052671 @default.
• W2029205267 hasOpenAccess W2029205267 @default.
• W2029205267 hasPrimaryLocation W20292052671 @default.
• W2029205267 hasRelatedWork W2015402259 @default.
• W2029205267 hasRelatedWork W2029205267 @default.
• W2029205267 hasRelatedWork W2043366791 @default.
• W2029205267 hasRelatedWork W2053631011 @default.
• W2029205267 hasRelatedWork W2077157877 @default.
• W2029205267 hasRelatedWork W2086620010 @default.
• W2029205267 hasRelatedWork W2094990782 @default.
• W2029205267 hasRelatedWork W2408770398 @default.
• W2029205267 hasRelatedWork W3031431514 @default.
• W2029205267 hasRelatedWork W3013470284 @default.
• W2029205267 hasVolume "17" @default.
• W2029205267 isParatext "false" @default.
• W2029205267 isRetracted "false" @default.
• W2029205267 magId "2029205267" @default.
• W2029205267 workType "article" @default.